A Phase 2 interventional study of Ociperlimab and Tislelizumab in Advanced Hepatocellular Carcinoma, sponsored by BeiGene. Completed at 28 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tislelizumab in Carcinoma, Hepatocellular — 23 open to participants now, 25 under way, 2 of them phase 3. tislelizumab · Carcinoma, Hepatocellular.
Among the 43 studies testing tislelizumab in Carcinoma, Hepatocellular, this one is the 11th largest by enrollment, is one of 8 that started in 2021, is one of 31 in phase 2, and was the 11th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →23 of the 43 studies testing tislelizumab in Carcinoma, Hepatocellular are open now, in 2 countries. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
First Hospital of China Medical University · Sites in China
Ages 18–80
Tongji Hospital · Sites in China
Ages 18+
Haibo Shao · Sites in China
Ages 18–80
Sir Run Run Shaw Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 32 · Phase 3 4 · Phase 4 1
First in 2017; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 94 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 40 across the 43 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 9 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
5 of the studies testing tislelizumab in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04615143Sun Yat-sen UniversityTislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC | 2026-12-01 |
| NCT07413354Tongji HospitalTislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma | 2027-03-31 |
| NCT07483359First Hospital of China Medical UniversityConversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus | 2027-06 |
| NCT05366829Rutgers, The State University of New JerseyTislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | 2027-06-01 |
| NCT07243691Sir Run Run Shaw HospitalStudy on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies testing tislelizumab in Carcinoma, Hepatocellular, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a Phase 2, randomized, multicenter, open-label, 2-arm study to investigate the efficacy and safety of ociperlimab in combination with tislelizumab plus BAT1706, and tislelizumab plus BAT1706, as first-line treatment in participants with advanced Hepatocellular Carcinoma (HCC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Criteria:
Inclusion Criteria:
Exclusion Criteria:
NOTE: Other protocol Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received tislelizumab 200 milligrams (mg) intravenously once every 3 weeks followed by BAT1706 15 milligrams per kilogram (mg/kg) intravenously once every 3 weeks followed by ociperlimab 900 mg intravenously once every 3 weeks in 21-day treatment cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.
Drug: Ociperlimab · Drug: Tislelizumab · Drug: BAT1706
Participants received tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks in 21-day treatment cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.
Drug: Tislelizumab · Drug: BAT1706
900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
Also known as: BGB-A1217
200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
Also known as: BGB-A317
15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
Also known as: Bevacizumab Injection
Objective Response Rate (ORR) as Assessed by the Investigator
ORR was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors version(v) 1.1 (RECIST v1.1). Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first (i.e., up to 27 months)
Duration Of Response (DOR) as Assessed by the Investigator
DOR was defined as the time from the date of first documentation of a partial response (PR) or better to the date of first documentation of progressive disease or death whichever comes first, assessed based on RECIST v1.1. Median DOR was estimated using the Kaplan-Meier method. Per RECIST v1.1, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
Time frame: From the first confirmed objective response until the first documentation of disease progression or death, whichever came first (i.e. up to 27 months)
Time to Response (TTR) as Assessed by the Investigator
TTR was defined as the time from the randomization date to the date of first documented partial response (PR) or better by the investigator, assessed based on RECIST v1.1. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From the randomization date to the first documentation of response (up to 27 months)
Disease Control Rate (DCR) as Assessed by the Investigator
DCR was defined as the percentage of participants who achieve complete response (CR), partial response (PR) or stable disease (SD), assessed based on RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first (i.e., up to 27 months)
Clinical Benefit Rate (CBR) as Assessed by the Investigator
CBR was defined as the percentage of participants who achieve complete response (CR), partial response (PR), or durable stable disease (stable disease defined as \>= 24 weeks). Per RECIST 1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first (i.e., up to 27 months)
Progression-Free Survival (PFS) as Assessed by the Investigator
PFS was evaluated by the investigator according to RECIST version 1.1; and was defined as the time from the randomization date to the date of first documentation of disease progression or date of death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Per RECIST v 1.1, progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
Time frame: From the randomization date to the date of first documentation of disease progression or death, whichever came first (i.e., up to 27 months)
Overall Survival (OS)
OS was defined as the time from the randomization date until the date of death from any cause. Median OS was estimated using the Kaplan-Meier method.
Time frame: From the randomization date until the date of death from any cause (up to 27 months)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
A TEAE was defined as an adverse event (AE) that had an onset date or a worsening in severity from baseline (pretreatment) on or after the first dose of study drug(s) and up to 30 days after the last dose of study drug(s), or initiation of new anticancer therapy, whichever occurs first. AEs were graded for severity using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0, where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; and Grade 5: Death related to AE. The TEAEs leading to death in this data table exclude death due to disease under study.
Time frame: From the date of the first dose of study drug up to 30 days after last dose of study drug (i.e., up to 27 months)
Serum Concentrations of Ociperlimab
Serum samples were assayed for ociperlimab concentrations using a validated immunoassay. This outcome measure was not analyzed for Arm B as ociperlimab was not administered in Arm B.
Time frame: Predose on Day 1 of Cycles 1, 2, 5, 9 and 17; Post dose on Day 1 of Cycles 1 and 5 and Safety Follow-up Visit (i.e., up to 30 days after last dose [up to 27 months]) (each cycle duration = 21-days)
Serum Concentrations of Tislelizumab
Serum samples were assayed for tislelizumab concentrations using a validated immunoassay.
Time frame: Predose on Day 1 of Cycles 1, 2, 5, 9 and 17; Post dose on Day 1 of Cycles 1 and 5 and Safety Follow-up Visit (i.e., up to 30 days after last dose [up to 27 months]) (each cycle duration = 21-days)
Serum Concentrations of BAT1706
Serum samples were assayed for BAT1706 concentrations using a validated immunoassay.
Time frame: Predose on Day 1 of Cycles 1, 2, 5, 9 and 17; Post dose on Day 1 of Cycles 1 and 5 and Safety Follow-up Visit (i.e., up to 30 days after last dose [up to 27 months]) (each cycle duration = 21-days)
Number of Participants With Antidrug Antibodies (ADAs) to Ociperlimab, Tislelizumab, and BAT1706
Serum samples were tested for the presence of ADAs to ociperlimab, tislelizumab and BAT1706 using a validated immunoassay. The analysis included: Treatment-emergent ADA: sum of treatment-boosted ADA patients and treatment-induced ADA participants as a percentage of the ADA-evaluable participants population; Treatment-boosted ADA: Baseline-positive ADA-evaluable patients with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period; and Treatment-induced ADA: ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period.
Time frame: Up to 27 months
A total of 94 eligible participants were randomized in a 2:1 ratio to receive ociperlimab in combination with tislelizumab + BAT1706 or tislelizumab + BAT1706.
| Milestone | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| Started | 62 | 32 |
| Treated | 62 | 31 |
| Completed | 0 | 0 |
| Not completed | 62 | 32 |
| Withdrew: Progressive disease | 27 | 18 |
| Withdrew: Adverse event | 14 | 4 |
| Withdrew: Participant moved to long term extension study | 7 | 4 |
| Withdrew: Withdrawal by subject | 10 | 0 |
| Withdrew: Closed by sponsor | 3 | 2 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Other-miscellaneous | 1 | 0 |
| Withdrew: Randomized but not treated | 0 | 1 |
ORR was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors version(v) 1.1 (RECIST v1.1). Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| Objective Response Rate (ORR) as Assessed by the Investigator | 37.1 (25.2 to 50.3) | 40.6 (23.7 to 59.4) |
DOR was defined as the time from the date of first documentation of a partial response (PR) or better to the date of first documentation of progressive disease or death whichever comes first, assessed based on RECIST v1.1. Median DOR was estimated using the Kaplan-Meier method. Per RECIST v1.1, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
| months | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| Duration Of Response (DOR) as Assessed by the Investigator | 12.6 (6.9 to NA) | 12.4 (5.4 to NA) |
TTR was defined as the time from the randomization date to the date of first documented partial response (PR) or better by the investigator, assessed based on RECIST v1.1. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| months | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| Time to Response (TTR) as Assessed by the Investigator | 2.76 (1.2 to 6.9) | 4.17 (1.4 to 8.3) |
DCR was defined as the percentage of participants who achieve complete response (CR), partial response (PR) or stable disease (SD), assessed based on RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of participants | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| Disease Control Rate (DCR) as Assessed by the Investigator | 77.4 (65.0 to 87.1) | 71.9 (53.3 to 86.3) |
CBR was defined as the percentage of participants who achieve complete response (CR), partial response (PR), or durable stable disease (stable disease defined as \>= 24 weeks). Per RECIST 1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| Clinical Benefit Rate (CBR) as Assessed by the Investigator | 59.7 (46.4 to 71.9) | 56.3 (37.7 to 73.6) |
PFS was evaluated by the investigator according to RECIST version 1.1; and was defined as the time from the randomization date to the date of first documentation of disease progression or date of death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Per RECIST v 1.1, progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
| months | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| Progression-Free Survival (PFS) as Assessed by the Investigator | 8.3 (5.5 to 10.3) | 6.9 (4.1 to 17.4) |
OS was defined as the time from the randomization date until the date of death from any cause. Median OS was estimated using the Kaplan-Meier method.
| months | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| Overall Survival (OS) | 19.7 (18.4 to NA) | 22.9 (14.4 to NA) |
A TEAE was defined as an adverse event (AE) that had an onset date or a worsening in severity from baseline (pretreatment) on or after the first dose of study drug(s) and up to 30 days after the last dose of study drug(s), or initiation of new anticancer therapy, whichever occurs first. AEs were graded for severity using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0, where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; and Grade 5: Death related to AE. The TEAEs leading to death in this data table exclude death due to disease under study.
| Participants | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| TEAEs | 62 | 31 |
| Serious TEAEs | 31 | 12 |
| TEAEs >= Grade 3 | 48 | 17 |
| TEAEs Leading to Treatment Discontinuation | 18 | 6 |
| TEAEs Leading to Death Excluding Death Due to Disease Under Study | 3 | 0 |
Serum samples were assayed for ociperlimab concentrations using a validated immunoassay. This outcome measure was not analyzed for Arm B as ociperlimab was not administered in Arm B.
| micrograms per milliliters (mcg/mL) | Arm A: Ociperlimab + Tislelizumab + BAT1706 |
|---|---|
| Cycle 1 Day 1: Pre-dose | 0.00 ± 0.000 |
| Cycle 1 Day 1: Post-dose | 287.15 ± 50.203 |
| Cycle 2 Day 1: Pre-dose | 39.82 ± 16.896 |
| Cycle 5 Day 1: Pre-dose | 68.23 ± 28.422 |
| Cycle 5 Day 1: Post-dose | 385.22 ± 79.227 |
| Cycle 9 Day 1: Pre-dose | 79.83 ± 30.614 |
| Cycle 17 Day 1: Pre-dose | 78.16 ± 29.558 |
| Safety Follow-up: Post Dose | 34.54 ± 28.961 |
Serum samples were assayed for tislelizumab concentrations using a validated immunoassay.
| micrograms per milliliters (mcg/mL) | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| Cycle 1 Day 1: Pre-dose | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Cycle 1 Day 1: Post-dose | 69.63 ± 11.923 | 67.69 ± 12.545 |
| Cycle 2 Day 1: Pre-dose | 19.65 ± 6.348 | 17.70 ± 5.875 |
| Cycle 5 Day 1: Pre-dose | 38.14 ± 13.908 | 36.62 ± 11.920 |
| Cycle 5 Day 1: Post-dose | 106.93 ± 22.321 | 103.21 ± 21.305 |
| Cycle 9 Day 1: Pre-dose | 43.82 ± 16.823 | 42.00 ± 16.495 |
| Cycle 17 Day 1: Pre-dose | 39.35 ± 14.060 | 44.01 ± 21.788 |
| Safety Follow-up: Post Dose | 23.90 ± 16.674 | 25.66 ± 26.011 |
Serum samples were assayed for BAT1706 concentrations using a validated immunoassay.
| micrograms per milliliters (mcg/mL) | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| Cycle 1 Day 1: Pre-dose | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Cycle 1 Day 1: Post-dose | 319.29 ± 58.599 | 321.03 ± 56.151 |
| Cycle 2 Day 1: Pre-dose | 63.28 ± 19.302 | 55.30 ± 20.999 |
| Cycle 5 Day 1: Pre-dose | 113.97 ± 37.045 | 112.79 ± 34.114 |
| Cycle 5 Day 1: Post-dose | 432.60 ± 86.670 | 410.71 ± 90.747 |
| Cycle 9 Day 1: Pre-dose | 113.72 ± 38.039 | 120.55 ± 43.141 |
| Cycle 17 Day 1: Pre-dose | 111.29 ± 31.055 | 123.36 ± 44.184 |
| Safety Follow-up: Post Dose | 59.74 ± 40.020 | 81.42 ± 79.696 |
Serum samples were tested for the presence of ADAs to ociperlimab, tislelizumab and BAT1706 using a validated immunoassay. The analysis included: Treatment-emergent ADA: sum of treatment-boosted ADA patients and treatment-induced ADA participants as a percentage of the ADA-evaluable participants population; Treatment-boosted ADA: Baseline-positive ADA-evaluable patients with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period; and Treatment-induced ADA: ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period.
| Participants | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| Treatment-emergent ADA: Ociperlimab | 1 | — |
| Treatment boosted ADA: Ociperlimab | 0 | — |
| Treatment induced ADA: Ociperlimab | 1 | — |
| Treatment-emergent ADA: Tislelizumab | 22 | 18 |
| Treatment boosted ADA: Tislelizumab | 1 | 2 |
| Treatment induced ADA: Tislelizumab | 21 | 16 |
| Treatment-emergent ADA: BAT1706 | 1 | 3 |
| Treatment boosted ADA: BAT1706 | 0 | 0 |
| Treatment induced ADA: BAT1706 | 1 | 3 |
Collected over All cause-mortality data was collected from randomization through end of the study (i.e. up to 29 months). Serious adverse events (SAEs) and non-serious AEs (NSAEs) data were collected from the date of the first dose of study drug up to 30 days after last dose of study drug (up to 27 months). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Ociperlimab + Tislelizumab + BAT1706 | 28/62 (45.2%) | 31/62 (50%) | 61/62 (98.4%) |
| Arm B: Tislelizumab + BAT1706 | 14/32 (43.8%) | 12/31 (38.7%) | 31/31 (100%) |
| Event | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| PneumoniaInfections and infestations | 2/62 | 2/31 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/62 | 1/31 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/62 | 1/31 |
| Intra-abdominal fluid collectionGastrointestinal disorders | 0/62 | 1/31 |
| NauseaGastrointestinal disorders | 0/62 | 1/31 |
| SubileusGastrointestinal disorders | 0/62 | 1/31 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/62 | 1/31 |
| VomitingGastrointestinal disorders | 0/62 | 1/31 |
| Cholecystitis acuteHepatobiliary disorders | 0/62 | 1/31 |
| Hepatic function abnormalHepatobiliary disorders | 1/62 | 1/31 |
| Event | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 |
|---|---|---|
| ProteinuriaRenal and urinary disorders | 24/62 | 16/31 |
| HypertensionVascular disorders | 23/62 | 15/31 |
| Aspartate aminotransferase increasedInvestigations | 26/62 | 9/31 |
| Alanine aminotransferase increasedInvestigations | 23/62 | 8/31 |
| Platelet count decreasedInvestigations | 23/62 | 8/31 |
| DiarrhoeaGastrointestinal disorders | 10/62 | 10/31 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 12/62 | 10/31 |
| HypothyroidismEndocrine disorders | 7/62 | 9/31 |
| Blood bilirubin increasedInvestigations | 10/62 | 8/31 |
| RashSkin and subcutaneous tissue disorders | 15/62 | 6/31 |
Analysis was performed on Intent-to-Treat (ITT) analysis set that included all randomized participants and were analyzed according to their randomized treatment arm (i.e., Arm A or Arm B).
| Age, Continuous(years) | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 | Total |
|---|---|---|---|
| Mean | 58.4 ± 11.27 | 59.1 ± 10.77 | 58.6 ± 11.05 |
| Sex: Female, Male(Participants) | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 | Total |
|---|---|---|---|
| Female | 5 | 2 | 7 |
| Male | 57 | 30 | 87 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 62 | 32 | 94 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 62 | 32 | 94 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Macrovascular invasion (MVI) Status(Participants) | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 | Total |
|---|---|---|---|
| Present | 13 | 12 | 25 |
| Absent | 49 | 20 | 69 |
| Extrahepatic spread (EHS) Status(Participants) | Arm A: Ociperlimab + Tislelizumab + BAT1706 | Arm B: Tislelizumab + BAT1706 | Total |
|---|---|---|---|
| Present | 31 | 19 | 50 |
| Absent | 31 | 13 | 44 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Aug 2021 to primary completion in Feb 2024, 29 months.
Results were first posted in Feb 2025, 1 year after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 29 months is below that.
Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tislelizumab · BAT1706